Based on the ODYSSEY COMBO II trial.

Alirocumab drug improves cholesterol levels compared to ezetimibe significantly The investigational drug alirocumab improved cholesterol levels in comparison to ezetimibe significantly, when added to regular statin therapy in patients with raised chlesterol and elevated risk of cardiovascular disease , based on the ODYSSEY COMBO II trial, presented as a Hot Line today at ESC Congress 2014. The findings suggest that adding alirocumab to founded statin regimens might provide an important new option to achieve required reductions in low-density lipoprotein cholesterol levels in risky patients, said the study's principal investigator, Christopher Cannon, MD, from the Harvard Clinical Research Institute in Boston, Massachusetts, USA .

‘These data mark the beginning of a steady stream of clinical leads to emerge from the Alkermes pipeline and solidify our placement as an R&D innovator. We believe Alkermes handles probably the most interesting CNS pipelines in the market, backed by a solid financial engine that enables us to invest in our future development, and we anticipate data for three additional candidates within the next 12 months: ALKS 3831, ALKS 8700 and ALKS 7106.’ Quarter Ended March 31, 2014 Highlights Total revenues for the one fourth were $130.2 million, compared to $163.4 million for the same period in the prior year, including $30.0 million of intellectual property permit revenue unrelated to key advancement programs.